4th April, 2024

(1) BSE Limited
Listing Department,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001

Scrip Code: 500087

(2) National Stock Exchange of India Limited
Listing Department
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051
Scrip Code: CIPLA EQ

(3) SOCIETE DE LA BOURSE DE LUXEMBOURG
Societe Anonyme
35A Boulevard Joseph II,
L-1840 Luxembourg

Dear Sir/Madam,

Sub: USFDA inspection at Company's manufacturing facility in Patalganga, Maharashtra, India

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby notify that a routine current Good Manufacturing Practices (cGMP) inspection was conducted by the United States Food and Drug Administration (USFDA) at the manufacturing facility of the Company located in Patalganga, Maharashtra, India from 28th March, 2024 to 4th April, 2024.

On conclusion of the inspection, the Company has received 6 inspectional observations in Form 483. The Company will work closely with the USFDA and is committed to address these comprehensively within the stipulated time.

Please take the above information on record.

Yours faithfully,
For Cipla Limited

RAJENDRA KUMAR CHOPRA
Digitally signed by RAJENDRA KUMAR CHOPRA
Date: 2024.04.04 22:16:28 +05'30'

Rajendra Chopra
Company Secretary

Prepared by: Mandar Kurghode